QIAGEN announced that the comprehensive QuantiFERON immune response blood tests have been recommended for use by clinicians in Tunisia to help kidney disease, transplant and dialysis patients.
This is the first time in the world that a professional body for renal medicine has issued such a recommendation, says the Netherlands-based company.
In order to detect potentially life-threatening complications as early as possible, the Tunisian Society of Nephrology (STN) advises specialist clinicians to use QuantiFERON-CMV to determine the strength of their immune system more generally, and QuantiFERON-TB Gold Plus to detect latent tuberculosis infection (LTBI) before it becomes an active disease.
“The world’s first recommendation by kidney specialists is a vote of confidence in QIAGEN’s QuantiFERON immune response tests,” said Simona Grandits, Senior Director, Head of Sales and Marketing EEMEA at QIAGEN.
“Tunisian clinicians will find QuantiFERON-CMV an innovative patient management tool to complement the PCR test for CMV – and QuantiFERON Monitor and QuantiFERON-TB Gold Plus an invaluable tool for monitoring specific and broader immune responses. They will be able to tailor preventive treatment and reduce the use of potentially toxic and expensive drugs,” she said, quoted by Globe Newswire.
